Sugar alcohol supplement
Inositol (Myo + D-Chiro)
Inositol (myo + D-chiro): the app lists a 5-hour half-life, none of the sources reviewed here states one, and the trials reviewed are mostly in polycystic ovary syndrome.
Inositol (Myo + D-Chiro) after one dose: 50% at ~5 h, 25% at 10 h, 12.5% at 15 h.
Drawn from the half-life in the app's model, ~5 h. The model's figures
- Compound
- Inositol (Myo + D-Chiro)
- Symbol
- INO
- Family
- Supplements
- Parts
- 13
- References
- 15
- Checked
- Last reviewed . Sources are listed below.
Overview
An FDA letter on a food-ingredient notice describes inositol as a white crystalline powder also known as myo-inositol, and a 2025 JAMA trial describes myo-inositol as "categorized as a sugar alcohol naturally present in the human body".1,2 The app's entry is for myo-inositol with D-chiro-inositol in a 40:1 ratio, its note calls this the studied protocol, and the app grades the evidence strong. Three trials reviewed here included a 40:1 myo-inositol to D-chiro-inositol arm: Benelli and colleagues (University of Pisa, 2016), Nordio and colleagues (Sapienza University, 2019) and Gul and colleagues (Khyber Medical University, 2025).3,4,5 Nordio and Proietti (Sapienza University of Rome, 2012) also compared a combined myo-inositol and D-chiro-inositol therapy with myo-inositol alone, and their record describes the combination as being in the "physiological plasma ratio (40:1)".13 Greff and colleagues pooled 26 randomised trials of inositols in polycystic ovary syndrome (PCOS), with 1691 women, in Reproductive Biology and Endocrinology in 2023, and report a higher rate of cycle normalization with inositol than placebo (RR = 1.79, CI: 1.13; 2.85), based on two eligible studies and graded very low in the review's Table 2.6 The 2018 Cochrane review of subfertile women with PCOS, which rated its evidence "low" to "very low" quality, says "We are uncertain whether MI improves live birth rates when compared to standard treatment among women undergoing IVF".7 A 2023 Cochrane review of seven trials (1319 women) on gestational diabetes reports that myo-inositol "may reduce the incidence of gestational diabetes" (RR 0.53, 95% CI 0.31 to 0.90) with low to very low certainty, and describes the studies as having relatively small sample sizes; the later 2025 JAMA trial of 464 pregnant women with PCOS had a different primary outcome, a composite of gestational diabetes, preeclampsia or preterm birth, which occurred in 25.0% on myo-inositol and 26.8% on placebo.8,2 Panic disorder trials in 1995 and 2001 gave inositol at 12 to 18 g/day (the 2001 paper calls it myo-inositol), and a 2014 meta-analysis of inositol in depression and anxiety reported "no statistically significant effects of inositol on depressive, anxiety, and obsessive-compulsive symptoms" together with marginally more responders in depression than placebo (p = 0.06).9,10,11
How it works
Sources in this part
The MYPP trial authors write that myo-inositol is "synthesized endogenously in relatively large quantities, ie, approximately 4 g daily, mainly by the kidneys".2 The FDA letter repeats a notifier's statement that "the adult human kidney" "produces an estimated 4,000 mg of inositol per day".1 Benelli and colleagues write that "As insulin second messengers, both these molecules are involved in increasing insulin sensitivity of different tissues", and that "DCI promotes glycogen synthesis, while MI may support glucose cell intake".3 These are statements in the paper's introduction and discussion, not measurements made in its trial.3 The same paper gives the 40:1 ratio as the physiological one, citing earlier work: "Facchinetti et al. discovered that the physiological MI/DCI ratio was 40 : 1".3 Nordio and colleagues write that their human results "validate a previous preclinical study with different MI/DCI ratios carried out in an experimental model of PCOS mice", and that trial had 8 women in each ratio group.4
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~5 h
- Bioavailability
- 99%
- Typical dose
- 2–4 g/day
- Route
- Oral
- Time to peak
- ~3 h
Sources in this part
The app lists a half-life of about 5 hours, bioavailability of 99% and a time to peak of about 3 hours. None of the sources reviewed here states a figure for inositol's half-life, bioavailability or time to peak.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~5 h | No half-life figure is stated in the sources reviewed. |
| Bioavailability | 99% | A single-dose trial in 20 healthy volunteers reported that powder and soft gelatin capsule forms of myo-inositol "resulted in a different bioavailability"; the PubMed record gives no percentage12 |
| Time to peak | ~3 h | No time-to-peak figure is stated; the FDA letter relays a notifier's summary of a 1975 report that inositol "is slowly absorbed in the gastrointestinal tract"1 |
The same summary says inositol is "mainly metabolized in the kidney, and excreted in urine", based on human and rat data reviewed in that 1975 report.1
Carlomagno and colleagues (Expert Opinion on Drug Delivery, 2012) also report that "MI soft gelatin capsule form showed similar PK parameters compared with three times higher doses of MI in powder form".12
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Van der Wel and colleagues (MYPP), JAMA 20252 | Double-blind, placebo-controlled randomised trial at 13 hospitals in the Netherlands; funded by ZonMw2 | 464 pregnant individuals with PCOS2 | Myo-inositol 2 g with 0.2 mg folic acid twice daily, or placebo with 0.2 mg folic acid, until delivery2 | Composite of gestational diabetes, preeclampsia or preterm birth in 25.0% (56) against 26.8% (61); RR 0.93 (95% CI 0.68-1.28; P = .67)2 |
| Benelli and colleagues, Int J Endocrinol 20163 | Randomised, folic acid comparator; authors declare no competing interests3 | 46 women with PCOS and obesity (21 and 25 per group)3 | 40:1 MI plus DCI (550 mg MI, 13.8 mg DCI, 200 µg folic acid) twice a day, or 200 µg folic acid; 6 months3 | Fasting insulin 20.19 ± 8.14 to 10.74 ± 5.46 µU/mL on the mixture; placebo 18 ± 8 to 17.8 ± 8.2; BMI, FSH, androstenedione, DHEAS and fasting glucose did not change significantly in either group3 |
| Nordio and colleagues, Eur Rev Med Pharmacol Sci 20194 | Randomised comparison of seven MI/DCI formulations; the PubMed record states no funder or competing interests4 | 56 women with PCOS, 8 per group4 | 2 g of inositols twice a day for 3 months4 | Authors report the 40:1 ratio as best for restoring ovulation and the others as less effective; the PubMed record gives no figures4 |
| Nordio and Proietti, Eur Rev Med Pharmacol Sci 201213 | Randomised, MI+DCI against MI alone13 | 50 overweight women with PCOS13 | MI+DCI or MI alone for six months; doses not in the PubMed record13 | At six months both groups improved metabolic parameters with no significant difference; MI+DCI was more effective at three months13 |
| Gul and colleagues, Naunyn Schmiedebergs Arch Pharmacol 20255 | Randomised comparison with metformin; grant from a Pakistani national institute; no competing interests declared5 | 60 women with PCOS, 30 per group5 | 40:1 MI plus DCI or metformin for 12 weeks5 | Both improved insulin sensitivity (HOMA-IR); metformin "showed slightly better outcomes in certain parameters, such as insulin sensitivity and endocrine markers"5 |
| Greff and colleagues, Reprod Biol Endocrinol 20236 | Systematic review and meta-analysis of randomised trials in PCOS; no competing interests declared6 | 26 trials, 1691 women (806 inositol, 311 placebo, 509 metformin)6 | Myo-inositol or D-chiro-inositol, doses and lengths differed between trials6 | Against placebo: cycle normalization RR 1.79 (CI 1.13; 2.85; 2 studies, 118 women; very low); fasting insulin MD -2.78 µU/ml (-7.13; 1.57; 6 studies, 286 women; low); HOMA MD -0.23 (-1.19; 0.72; 3 studies, 92 women; low); BMI MD -0.45 kg/m2 (-0.89; -0.02; 8 studies, 419 women)6 |
| Showell and colleagues, Cochrane 20187 | Systematic review of randomised trials in subfertile women with PCOS7 | 13 trials, 1472 women7 | Oral inositol, mostly as IVF pre-treatment7 | Live birth OR 2.42 (95% CI 0.75 to 7.83; 2 trials, 84 women), "uncertain"; evidence low to very low quality7 |
| Motuhifonua and colleagues, Cochrane 20238 | Systematic review of randomised trials; gestational diabetes prevention8 | 7 trials, 1319 pregnant women (six in Italy, one in Ireland)8 | Myo-inositol alone or in a combination preparation; doses, timing and populations differed8 | Gestational diabetes RR 0.53 (95% CI 0.31 to 0.90; 6 studies, 1140 women); low to very low certainty8 |
| Benjamin and colleagues, Am J Psychiatry 19959 | Double-blind, placebo-controlled crossover9 | 21 patients with panic disorder9 | Inositol 12 g/day, 4 weeks9 | Panic attack frequency and severity declined "significantly more after inositol than after placebo"; "Side effects were minimal"9 |
| Palatnik and colleagues, J Clin Psychopharmacol 200110 | Double-blind, random-order crossover against fluvoxamine; no placebo arm10 | 20 patients with panic disorder who completed10 | Inositol up to 18 g/day or fluvoxamine up to 150 mg/day, 1 month each10 | Anxiety and global scores similar for both; in the first month panic attacks per week fell by 4.0 (2) with inositol and 2.4 (2) with fluvoxamine (p = 0.049)10 |
| Mukai and colleagues, Hum Psychopharmacol 201411 | Meta-analysis of double-blind placebo-controlled trials11 | 7 depression trials (n = 242) and 4 anxiety trials (n = 70)11 | Inositol; doses not in the PubMed record11 | No statistically significant effects on depressive, anxiety or obsessive-compulsive symptoms; marginally more responders in depression than placebo (p = 0.06); "marginally" more gastrointestinal upset (p = 0.06); the 4 anxiety trials were 2 obsessive-compulsive disorder, 1 panic disorder and 1 posttraumatic stress disorder study11 |
Deeper analysis: MYPP trial (van der Wel and colleagues, JAMA 2025)
Van der Wel and colleagues, with Laven and Fauser among the authors, ran a multicentre, double-blind, placebo-controlled trial at "4 academic hospitals and 9 nonacademic teaching hospitals in the Netherlands".2 Eligible participants were aged 18 or older with a viable singleton pregnancy at 8 to 16 weeks and a PCOS diagnosis by Rotterdam criteria; the exclusions included "preexistent type 1 or type 2 diabetes, kidney failure".2 The primary outcome was "a composite of gestational diabetes, preeclampsia, or preterm birth".2 The primary outcome did not differ (56 of 224 against 61 of 228; relative risk 0.93, 95% CI 0.68 to 1.28).2 The components were gestational diabetes 38 (17.0) against 36 (15.8), preeclampsia 5 (2.2) against 11 (4.8) and preterm birth 17 (7.6) against 21 (9.3), with relative risks of 1.07 (0.71 to 1.63), 0.46 (0.16 to 1.32) and 0.82 (0.44 to 1.51).2 Among secondary outcomes, planned (primary) cesarean delivery occurred in 13 (5.9%) against 26 (11.6%) (relative risk 0.51, 95% CI 0.27 to 0.97; P = .04) while overall cesarean rates were similar, and the authors write that this "may be coincidental".2 Adverse effects were reported by 6.9% on myo-inositol and 9.1% on placebo (relative risk 0.76, 95% CI 0.40 to 1.45), and glycated hemoglobin "did not differ between the groups".2 In the neonatal table, stillbirth occurred in 1 (0.5) on myo-inositol against 4 (1.8) on placebo and neonatal death in 2 (0.9) against 1 (0.5), and other neonatal outcomes were similar in both groups.2 The authors list limitations: biochemical hyperandrogenism was higher in the myo-inositol group (23.5% vs 15.5%) "by chance", the primary event rate was "lower than anticipated (25.9% vs the expected 33.0%)", and good adherence (at least 80% of supplements) was 38.9% and 31.3% in the two groups in the limitations paragraph, while the results text gives 38.9% and 30.7%.2 The authors write that "These findings contradict previously reported beneficial effects observed in 3 randomized clinical trials in individuals at risk of gestational diabetes and related pregnancy complications", and name those trials' "relatively small sample size (between 197 and 220 participants) and the open-label design" as potential limitations.2 The trial was funded by ZonMw, and "The supplements for both the intervention and placebo group were purchased from and manufactured by Gynov SAS (Bordeaux, France)", a company the paper says "had no role in trial funding, design, execution, data analysis, or manuscript preparation".2 Author disclosures include fees and grants from several companies, none of them Gynov SAS, and the statement ends "No other disclosures were reported".2 The trial tested 4 g/day of myo-inositol with 0.4 mg of folic acid against folic acid only, in pregnancy with PCOS; it did not test the 40:1 mixture or non-pregnant women.2
Deeper analysis: Benelli and colleagues (40:1 mixture against folic acid, 2016)
Benelli and colleagues, University Hospital of Pisa, enrolled 46 women with PCOS and BMI above 30, excluding "Patients with diabetes, smokers, and alcohol users".3 The mixture group (21 women) took the 40:1 soft gel capsule twice a day and the comparison group (25 women) took 200 μg folic acid as placebo for six months.3 The authors report "a statistically significant reduction of LH, free testosterone, fasting insulin, and HOMA index only in the group treated with the combined therapy", with HOMA 3.38 ± 1.97 to 1.97 ± 1.48 on the mixture.3 The Methods describe a "Paired t-test" comparing baseline with six months within each group, and the text fetched reports no between-group test.3 The paper states "no relevant side effect was recorded during the combined therapy with MI plus DCI".3 The authors say "more studies on a higher number of patients and with greater statistical significance are needed to confirm these striking posttreatment outcomes".3 The capsules were a branded product (INOFOLIC COMBI, LO.LI.PHARMA); the text fetched contains no funding statement, and the authors declare no competing interests.3
Deeper analysis: Greff and colleagues (meta-analysis of inositols in PCOS, 2023)
Its stated conclusion is "Inositol is an effective and safe treatment in PCOS", with BMI, free testosterone, total testosterone, androstenedione, glucose and AUC insulin lower than placebo and sex-hormone-binding globulin higher.6 The pooled fasting insulin and HOMA results against placebo did not reach significance (MD -2.78, CI -7.13 to 1.57; MD -0.23, CI -1.19 to 0.72), each graded "low" in its Table 2.6 For the combination of myo- and D-chiro-inositol against placebo the table holds one study of 46 women, with free testosterone MD -0,12 (-0.28; 0.04) and HOMA MD -0.73 (-2.2; 0.74).6 For the same combination against placebo the table also lists fasting insulin from one study of 46 women, MD -9.25 µU/ml (-15.57; -2.93), graded high.6 Four placebo-controlled studies reported no side effects for inositols, and in four metformin comparisons side effects were 7% against 53% (RR = 0.16, CI: 0.09; 0.28), with bloating, nausea and generalized weakness on metformin.6 The authors name "the small number of studies with small sample size, and the heterogeneous populations", different follow-up times and "moderate and high risk of bias in some domains" as limitations.6 It was supported by a Hungarian national research office grant, whose agency "had no role in the design, data collection, analysis, interpretation, and manuscript preparation", and the authors declare no competing interests.6
Deeper analysis: Cochrane review of inositol in subfertile women with PCOS (2018)
Showell and colleagues searched to July 2018 and included 13 trials of 1472 women, 11 of them in IVF pre-treatment and two in ovulation induction.7 The review lists "serious risk of bias due to poor reporting of methods, inconsistency, and lack of reporting of clinically relevant outcomes such as live birth and adverse events" as its main limitations.7 For miscarriage the pooled odds ratio was 0.40 (95% CI 0.19 to 0.86; 4 RCTs; 535 women; I² = 66%), but "When we removed this trial from the sensitivity analysis, we no longer saw the effect".7 The authors state "all trials used a standard treatment control, thus possibly overestimating the effect of inositol".7 The review reports "Trials did not clearly report adverse events", and its first author declares no conflicts of interest.7
Deeper analysis: panic disorder trials (Benjamin 1995, Palatnik 2001)
Benjamin and colleagues (Soroka Medical Center, Beersheba) completed a 4-week crossover of 12 g/day inositol against placebo in 21 patients and report the frequency and severity of panic attacks fell "significantly more after inositol than after placebo".9 Palatnik and colleagues (Ben Gurion University of the Negev) compared inositol up to 18 g/day with fluvoxamine up to 150 mg/day in 20 completers, with no placebo arm, and report that "Nausea and tiredness were more common with fluvoxamine".10 Neither PubMed record states a funder or the authors' limitations, and both tested inositol alone in people with panic disorder rather than the 40:1 mixture (only the 2001 record calls it myo-inositol).9,10 The 2014 meta-analysis (Mukai and colleagues, Fujita Health University) pooled 4 anxiety-disorder trials (n = 70) and states "The main limitation of this report is that a small number of studies were included in this meta-analysis".11
Doses reported in studies and on labels
The app lists 2 to 4 g/day. The trials below used 4 g/day (MYPP, Nordio 2019), about 1.1 g of myo-inositol with 27.6 mg of D-chiro-inositol per day (Benelli), and 12 to 18 g/day for panic disorder.2,4,3,9,10
| Source | Material, dose, route | Length | People and n | Comparator |
|---|---|---|---|---|
| MYPP, JAMA 20252 | Myo-inositol 2 g with 0.2 mg folic acid twice daily (4 g/day), oral sachets | Until delivery | 230 on myo-inositol, 234 on placebo; pregnant, PCOS | Placebo with 0.2 mg folic acid only |
| Benelli, 20163 | 40:1 MI plus DCI soft gel: 550 mg MI, 13.8 mg DCI, 200 µg folic acid, twice a day, oral | 6 months | 21 on the mixture, 25 on placebo; PCOS, obesity | 200 µg folic acid twice a day |
| Nordio, 20194 | 2 g of inositols twice a day in seven formulations, from DCI alone to 80:1 MI/DCI, oral | 3 months | 56 women with PCOS, 8 per group | Other ratios |
| Gul, 20255 | 40:1 MI plus DCI; dose not in the PubMed record | 12 weeks | 60 women with PCOS, 30 per group | Metformin |
| Benjamin, 19959 | Inositol 12 g/day | 4 weeks | 21 with panic disorder | Placebo, crossover |
| Palatnik, 200110 | Inositol up to 18 g/day | 1 month | 20 completers with panic disorder | Fluvoxamine up to 150 mg/day, crossover |
No product label or monograph with a dose was reviewed. The FDA letter gives food-use levels for an inositol notice (up to 120 mg/kg in beverages and up to 250 mg/kg in dry milks), which are concentrations in food, not doses.1
Side effects reported
Carlomagno and Unfer (AGUNCO Obstetrics and Gynecology Center, Rome) reviewed safety data and report that "only the highest dose of myo-inositol (12 g/day) induced mild gastrointestinal side effects such as nausea, flatus and diarrhea", and that "The severity of side effects did not increase with the dosage".14 The same review states that "despite its wide clinical use, there is still scarce information on the myo-inositol safety and/or side effects".14 In the MYPP trial (4 g/day), reported adverse effects were 6.9% on myo-inositol and 9.1% on placebo, with nausea in 7 (3.2) against 13 (5.9) and headache in 3 (1.4) against 1 (0.5).2 In the Mukai meta-analysis of depression and anxiety trials, inositol "marginally caused gastrointestinal upset compared with placebo (p = 0.06)".11 The 2023 Cochrane gestational diabetes review reports "no maternal adverse effects of therapy in the five studies that reported on this outcome; the other two studies did not mention this", and the 2018 Cochrane review reports that "Trials did not clearly report adverse events".8,7 Benjamin and colleagues describe side effects as "minimal" at 12 g/day.9
Bloodwork and markers
Sources in this part
The app lists fasting insulin and HbA1c as markers to monitor. In Benelli and colleagues' 46-woman trial, fasting insulin went from 20.19 ± 8.14 to 10.74 ± 5.46 µU/mL on the 40:1 mixture and from 18 ± 8 to 17.8 ± 8.2 on folic acid, while fasting glucose did not change significantly in either group.3 In the Greff meta-analysis, pooled fasting insulin against placebo was MD -2.78 µU/ml (-7.13; 1.57), and glucose was lower with inositol (MD = -3.14; CI: -5.75; -0.54).6 In the MYPP trial, glycated hemoglobin "was stable throughout pregnancy and did not differ between the groups".2
Regulatory and anti-doping status
Sources in this part
The FDA issued a letter on GRAS Notice No. GRN 001198, stating "we have no questions at this time regarding Sichuan Bohaoda" conclusion that inositol is GRAS under its intended conditions of use.1 The notice covers inositol as a nutrient supplement in flavored and enhanced waters, soft drinks, juices, fruit drinks and dry milks, and the letter says it "is not an affirmation that inositol is GRAS under 21 CFR 170.35".1 The letter describes the notifier's view and cites 21 CFR 184.1370 for inositol; it concerns the food ingredient and does not mention D-chiro-inositol or capsule supplements.1 The 2026 WADA Prohibited List came into effect on 1 January 2026, and the word inositol does not appear in its text as fetched (38,830 characters).15 No EMA, TGA or national drug-regulator document on inositol was reviewed.
What is not known
The sources reviewed give no figure for inositol's half-life, bioavailability or time to peak, so the app's 5 hours, 99% and 3 hours cannot be set beside a source figure. The only placebo-comparator trial of the 40:1 mixture in the sources reviewed is the 46-woman Benelli trial, which describes within-group tests, and Greff lists one study for the combination against placebo.3,6 The panic disorder trials used inositol alone at 12 to 18 g/day; the 1995 placebo-controlled crossover (21 patients, 4 weeks) reported panic attacks declining significantly more after inositol than after placebo, while the 2014 meta-analysis, whose anxiety-disorder analysis held 4 trials (n = 70, one in panic disorder), reports no statistically significant effect on anxiety symptoms, so the app's note that evidence is strong for anxiety is not clearly matched by these sources.9,10,11 The 2023 Cochrane gestational diabetes review notes that six of its seven trials were in Italy, "which raises concerns about the lack of generalisability to other settings".8 The app's note says the mixture is "often called 'nature's Ozempic'"; none of the sources reviewed compares inositol with a GLP-1 drug, and the pooled BMI difference against placebo in PCOS was MD = -0.45 kg/m2 (CI: -0.89; -0.02; 8 trials, 419 women).6
Frequently asked questions
What is the half-life of inositol?
The app lists about 5 hours, and none of the sources reviewed states a half-life figure.
What is the bioavailability of inositol?
The app lists 99%, and the one pharmacokinetic trial reviewed reports that myo-inositol powder and soft gelatin capsules "resulted in a different bioavailability" without a percentage in its PubMed record.12
What is the 40:1 ratio in inositol supplements?
It is the ratio of myo-inositol to D-chiro-inositol that Benelli and colleagues call "the physiological MI/DCI ratio".3
Is inositol banned by WADA?
The word inositol does not appear in the text of the 2026 WADA Prohibited List as fetched.15
Is inositol approved by the FDA?
The FDA issued a "no questions" letter on a GRAS notice for inositol as a food ingredient (GRN 001198), and the letter states it is not an affirmation that inositol is GRAS under 21 CFR 170.35.1
Did myo-inositol reduce pregnancy complications in women with PCOS?
In the 2025 JAMA trial of 464 pregnant women with PCOS, the composite of gestational diabetes, preeclampsia or preterm birth occurred in 25.0% on myo-inositol and 26.8% on placebo (relative risk 0.93, 95% CI 0.68 to 1.28).2
Does inositol lower fasting insulin?
Does inositol cause side effects?
A 2011 review reports that only the highest dose of myo-inositol studied (12 g/day) induced "mild gastrointestinal side effects such as nausea, flatus and diarrhea" and also states there is "still scarce information on the myo-inositol safety and/or side effects"; a 2014 meta-analysis of depression and anxiety trials reports that inositol "marginally caused gastrointestinal upset compared with placebo (p = 0.06)".14,11
Guides, tools and comparisons
References
- U.S. Food and Drug Administration. Response letter to GRAS Notice No. GRN 001198 (inositol), submitted by CIRS Group USA, Inc. for Sichuan Bohaoda Biological Technology Co., Ltd. FDA GRAS letter
- van der Wel AWT, et al. Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial. JAMA 2025. PMID 40920401
- Benelli E, et al. A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women. Int J Endocrinol 2016. PMID 27493664
- Nordio M, et al. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci 2019. PMID 31298405
- Gul M, et al. Comparative efficacy of combined myo-inositol and D-chiro inositol versus metformin across PCOS phenotypes. Naunyn Schmiedebergs Arch Pharmacol 2025. PMID 39847053
- Greff D, et al. Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol 2023. PMID 36703143
- Showell MG, et al. Inositol for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev 2018. PMID 30570133
- Motuhifonua SK, et al. Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. Cochrane Database Syst Rev 2023. PMID 36790138
- Benjamin J, et al. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995. PMID 7793450
- Palatnik A, et al. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol 2001. PMID 11386498
- Mukai T, et al. A meta-analysis of inositol for depression and anxiety disorders. Hum Psychopharmacol 2014. PMID 24424706
- Carlomagno G, et al. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin Drug Deliv 2012. PMID 22339497
- Nordio M, et al. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 2012. PMID 22774396
- Carlomagno G, et al. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci 2011. PMID 21845803
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list